Vera Therapeutics, Inc. $VERA Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC increased its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 232.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,519 shares of the company’s stock after purchasing an additional 40,196 shares during the quarter. Squarepoint Ops LLC owned 0.09% of Vera Therapeutics worth $1,355,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in VERA. Bollard Group LLC acquired a new stake in shares of Vera Therapeutics during the second quarter valued at about $1,509,000. Trexquant Investment LP boosted its holdings in Vera Therapeutics by 187.1% in the first quarter. Trexquant Investment LP now owns 62,777 shares of the company’s stock valued at $1,508,000 after purchasing an additional 40,913 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Vera Therapeutics during the 1st quarter valued at approximately $326,000. Hudson Bay Capital Management LP purchased a new stake in Vera Therapeutics during the 2nd quarter worth approximately $7,044,000. Finally, American Century Companies Inc. raised its position in shares of Vera Therapeutics by 89.3% in the 2nd quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock valued at $16,832,000 after purchasing an additional 336,978 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Up 7.4%

Vera Therapeutics stock opened at $51.22 on Friday. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.72. The firm’s 50-day moving average is $33.89 and its 200-day moving average is $27.30. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. The company has a market cap of $3.27 billion, a P/E ratio of -12.84 and a beta of 1.21.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the previous year, the business posted ($0.85) EPS. On average, equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Ratings Changes

VERA has been the subject of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. TD Cowen raised their price objective on shares of Vera Therapeutics from $60.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, December 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Wednesday, October 8th. Finally, Pivotal Research set a $73.00 price objective on Vera Therapeutics in a report on Friday, December 5th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $74.83.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, SVP Joseph R. Young sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $29.06, for a total value of $435,900.00. Following the sale, the senior vice president directly owned 47,839 shares in the company, valued at approximately $1,390,201.34. This trade represents a 23.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Patrick G. Enright purchased 5,882 shares of Vera Therapeutics stock in a transaction dated Thursday, December 11th. The shares were purchased at an average cost of $42.50 per share, with a total value of $249,985.00. Following the acquisition, the director owned 5,882 shares of the company’s stock, valued at approximately $249,985. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 16.30% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.